APO RESEARCH · REPORT
Biosimilar Drug
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
Product & engineering
Understand the product.
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
Selected research
Industry Research
Biosimilar Drug Industry Research Report 2026
Market perspective
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
In China, Biosimilar Drug key players include CP Guojian Pharma, Biotech Pharma, Celgen Pharma, etc. Global top three manufacturers hold a share over 70%.
Read the full market overview
East China is the largest market, with a share over 70%, followed by North China, with a share about 15 percent.
In terms of product, Tablets is the largest segment, with a share over 65%. And in terms of application, the largest application is Ankylosing Spondylitis, followed by Rheumatoid Arthrtis, Tumor, Cardiovascular, etc.
Report Scope
This report quantifies the global Biosimilar Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Dose), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Dose) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biosimilar Drug Market by Company
CP Guojian Pharma
Biotech Pharma
Celgen Pharma
Henlius
Amgen
Eli Lilly
Sandoz
Changchun High Tech
Innovent
Biosimilar Drug Segment by Type
Injection
Tablets
Other Types
Biosimilar Drug Segment by Application
Ankylosing Spondylitis
Tumor
Rheumatoid Arthrtis
Cardiovascular
Other Application
Biosimilar Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biosimilar Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biosimilar Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biosimilar Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Tablets
- Other Types
Applications
- Ankylosing Spondylitis
- Tumor
- Rheumatoid Arthrtis
- Cardiovascular
- Other Application
Companies covered
- CP Guojian Pharma
- Biotech Pharma
- Celgen Pharma
- Henlius
- Amgen
- Eli Lilly
- Sandoz
- Changchun High Tech
- Innovent
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Biosimilar Drug Market Size (2021-2032)
- 2.2.2 Global Biosimilar Drug Sales (2021-2032)
- 2.2.3 Global Biosimilar Drug Market Average Price (2021-2032)
- 2.3 Biosimilar Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Injection
- 2.3.3 Tablets
- 2.3.4 Other Types
- 2.4 Biosimilar Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Ankylosing Spondylitis
- 2.4.3 Tumor
- 2.4.4 Rheumatoid Arthrtis
- 2.4.5 Cardiovascular
- 2.4.6 Other Application
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Biosimilar Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Biosimilar Drug Sales (K Dose) of Manufacturers (2021-2026)
- 3.3 Global Biosimilar Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Biosimilar Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Biosimilar Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Biosimilar Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Biosimilar Drug, Product Type & Application
- 3.8 Global Manufacturers of Biosimilar Drug, Established Date
- 3.9 Global Biosimilar Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 CP Guojian Pharma
- 4.1.1 CP Guojian Pharma Company Information
- 4.1.2 CP Guojian Pharma Business Overview
- 4.1.3 CP Guojian Pharma Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 CP Guojian Pharma Biosimilar Drug Product Portfolio
- 4.1.5 CP Guojian Pharma Recent Developments
- 4.2 Biotech Pharma
- 4.2.1 Biotech Pharma Company Information
- 4.2.2 Biotech Pharma Business Overview
- 4.2.3 Biotech Pharma Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Biotech Pharma Biosimilar Drug Product Portfolio
- 4.2.5 Biotech Pharma Recent Developments
- 4.3 Celgen Pharma
- 4.3.1 Celgen Pharma Company Information
- 4.3.2 Celgen Pharma Business Overview
- 4.3.3 Celgen Pharma Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Celgen Pharma Biosimilar Drug Product Portfolio
- 4.3.5 Celgen Pharma Recent Developments
- 4.4 Henlius
- 4.4.1 Henlius Company Information
- 4.4.2 Henlius Business Overview
- 4.4.3 Henlius Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Henlius Biosimilar Drug Product Portfolio
- 4.4.5 Henlius Recent Developments
- 4.5 Amgen
- 4.5.1 Amgen Company Information
- 4.5.2 Amgen Business Overview
- 4.5.3 Amgen Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Amgen Biosimilar Drug Product Portfolio
- 4.5.5 Amgen Recent Developments
- 4.6 Eli Lilly
- 4.6.1 Eli Lilly Company Information
- 4.6.2 Eli Lilly Business Overview
- 4.6.3 Eli Lilly Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Eli Lilly Biosimilar Drug Product Portfolio
- 4.6.5 Eli Lilly Recent Developments
- 4.7 Sandoz
- 4.7.1 Sandoz Company Information
- 4.7.2 Sandoz Business Overview
- 4.7.3 Sandoz Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sandoz Biosimilar Drug Product Portfolio
- 4.7.5 Sandoz Recent Developments
- 4.8 Changchun High Tech
- 4.8.1 Changchun High Tech Company Information
- 4.8.2 Changchun High Tech Business Overview
- 4.8.3 Changchun High Tech Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Changchun High Tech Biosimilar Drug Product Portfolio
- 4.8.5 Changchun High Tech Recent Developments
- 4.9 Innovent
- 4.9.1 Innovent Company Information
- 4.9.2 Innovent Business Overview
- 4.9.3 Innovent Biosimilar Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Innovent Biosimilar Drug Product Portfolio
- 4.9.5 Innovent Recent Developments
5 Global Biosimilar Drug Market Scenario by Region
- 5.1 Global Biosimilar Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Biosimilar Drug Sales by Region: 2021-2032
- 5.2.1 Global Biosimilar Drug Sales by Region: 2021-2026
- 5.2.2 Global Biosimilar Drug Sales by Region: 2027-2032
- 5.3 Global Biosimilar Drug Revenue by Region: 2021-2032
- 5.3.1 Global Biosimilar Drug Revenue by Region: 2021-2026
- 5.3.2 Global Biosimilar Drug Revenue by Region: 2027-2032
- 5.4 North America Biosimilar Drug Market Facts & Figures by Country
- 5.4.1 North America Biosimilar Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Biosimilar Drug Sales by Country (2021-2032)
- 5.4.3 North America Biosimilar Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Biosimilar Drug Market Facts & Figures by Country
- 5.5.1 Europe Biosimilar Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Biosimilar Drug Sales by Country (2021-2032)
- 5.5.3 Europe Biosimilar Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Biosimilar Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Biosimilar Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Biosimilar Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Biosimilar Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Biosimilar Drug Market Facts & Figures by Country
- 5.7.1 South America Biosimilar Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Biosimilar Drug Sales by Country (2021-2032)
- 5.7.3 South America Biosimilar Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Biosimilar Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Biosimilar Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Biosimilar Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Biosimilar Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Biosimilar Drug Sales by Type (2021-2032)
- 6.1.1 Global Biosimilar Drug Sales by Type (2021-2032) & (K Dose)
- 6.1.2 Global Biosimilar Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Biosimilar Drug Revenue by Type (2021-2032)
- 6.2.1 Global Biosimilar Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Biosimilar Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Biosimilar Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Biosimilar Drug Sales by Application (2021-2032)
- 7.1.1 Global Biosimilar Drug Sales by Application (2021-2032) & (K Dose)
- 7.1.2 Global Biosimilar Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Biosimilar Drug Revenue by Application (2021-2032)
- 7.2.1 Global Biosimilar Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Biosimilar Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Biosimilar Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Biosimilar Drug Value Chain Analysis
- 8.1.1 Biosimilar Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Biosimilar Drug Production Mode & Process
- 8.2 Biosimilar Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Biosimilar Drug Distributors
- 8.2.3 Biosimilar Drug Customers
9 Global Biosimilar Drug Analyzing Market Dynamics
- 9.1 Biosimilar Drug Industry Trends
- 9.2 Biosimilar Drug Industry Drivers
- 9.3 Biosimilar Drug Industry Opportunities and Challenges
- 9.4 Biosimilar Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst